anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The aim of this study was to investigate the effects of dual task home based exercise program on balance, gait and cognitive functions. The study is planned to include 60 patients with Parkinson's disease, whose levels are 1-3 according to the Hoehn-Yahr scale and will be admitted to Istanbul University Capa Medical Faculty Neurology Department Movement and Behavior Disorders Unit between June 2019 and February 2020. The aim of the study, duration, possible side effects of treatment will be given to the volunteers to participate in the study. The "Informed Consent Form am prepared in accordance with the standards determined by the Clinical Research Ethics Committee of Istanbul Faculty of Medicine will be approved and the study will be conducted in accordance with the Declaration of Helsinki.

Patients who meet the inclusion criteria of the study will be included in the study and will be randomized into two groups. Both groups will be given information with brochures containing the importance of exercise in Parkinson's disease and DVD copies where the exercises are recorded weekly. The time and activity schedule created at the end of the brochures, daily recording of home exercises of the patients will be requested. Home exercise training and assessments will be provided by different physiotherapists. The evaluator physiotherapist will be blind to the treatment group to which the patient belongs. In the balance exercises group; 4 exercise packages which include static, dynamic and functional balance exercises will be taught in the first part of exercise period for 4 weeks. After the four weeks, the exercises should be progressed in the last 4 weeks in the second training session. In the dual task based balance exercises group; 4 exercise packages which include static, dynamic and functional balance exercises with cognitive or motor dual task will be taught in the first part of exercise period for 4 weeks. After the four weeks, the exercises should be progressed in the last 4 weeks in the second training session.

The number of subjects to be taken for each group in the 95% confidence interval was considered to be 26, considering the minimal clinical significant change (Minimal Clinically Important Difference, MCID) 3.5 for the Timed Up and Go Test. Considering that the patients did not continue treatment, it was decided to take 30 patients to each group and to carry out the study with a total of 60 patients. The primary outcomes are Mini Best Test,Timed Get Up and Go Test. Also objective datas will be obtained from Biodex Balance System, Wii Balance Board and G Walk Sensory Walking System.The secondary outcome measures include activity balance confidence scale, Parkinson's Disease Questionnaire-39 and cognitive tests such as number range test, verbal memory processes test, mental flexibility and word fluency test.
PURPOSE: To effectively extract a collagen component form the skin of swellfish. CONSTITUTION: A collagen component is extracted by boiling fresh skin of a swellfish in an aqueous solution containing alcohol such as SYOUTYUU (low-class distilled spirits) having deodorizing and sterilizing functions and concentrating the solution. The obtained collagen is boiled under stirring in water together with vegetable gelatin and a corrosion preventing agent such as granular potassium sorbate for preservation is added to the collagen solution while it is boiling. Powdery agar is added to the boiling collagen solution and the solution is continuously boiled to be concentrated. Subsequently, the concentrated solution is cooled to make it a semisolid state. An additive is added together with the corrosion preventing agent depending the use of the collagen, that is, a perfumery for cosmetic material and bathing agent, and a food additive for food.
The present invention relates to a mercapto modified dye and a preparation method for a mercapto modified dyeing agent, which belongs to the technical field of synthetic dyes and dyeing agents. The mercapto modified dye is R-phenol-2-hydroxy-3-mercapto-ether after R-phenol dye intermediate is modified by sulfhydrylation. The preparation method comprises the steps that the R-phenol dye intermediate and epoxychloropropane are etherified; an etherified product and NaSH make a mercapto-compound modified reaction so as to prepare the R-phenol-2-hydroxy-3-mercapto-ether. After the mercapto modified dye and an auxiliary dyeing agent are compounded, the mercapto modified dyeing agent is prepared. When the dyeing agent is smeared on hair, disulfide bonds in the dye and the hair exchange sulfur-sulfide bonds, and thereby, the hair is permanently dyed by the dye. The dye of the present invention has low toxicity, and the dyeing agent compounded from the dye has the advantages of long duration time of dyeing effect and natural and beautiful color; the principle of sulfur-sulfide bond exchange in a marcel mechanism is applied to the process of dyeing so as to break through the restriction of compounding the dyeing agents and oxidized dyeing agents from pure dyes.
The resilience enhancement group will begin with a 90-minute session with the study psychologist, which will include a brief introduction to cognitive behavioral therapy (CBT), but focus primarily on psychoeducational, relaxation techniques and planning positive activities. The majority of the time will be focused on reviewing techniques that promote stress management. Emphasis will be placed on relaxation approaches such as controlled breathing, meditation and yoga. Focus will also be aimed at reviewing how engagement in positive activities may help prevent avoidance, promote social support and wellness. Over the subsequent 6 weeks, daily text messages to all participants will accentuate the positive, including providing recommendations on beneficial activities to engage in, encouraging such activities including in vivo exposure, and fostering behavioral changes.
Self-assembling peptides or self-assembling peptidomimetics ("SAP") can treat inflammation or inflammatory diseases, or reduce one or more symptoms of diseases and disorders associated with undesirable inflammation. Topical and injectable compositions of SAP for local administration to a site of inflammation for reduction or prevention of symptoms of inflammatory diseases and disorders are described. The compositions include one or more SAP in an amount and concentration effective to reduce or prevent one or more symptoms of undesirable inflammation. The SAP can assemble prior to or after the composition is administered. The SAP form a structure within or at the surface of the body that prevents and/or reduces symptoms associated with inflammation and other dysregulated immune processes. The peptides can assemble upon contact with bodily fluids ( e.g. , synovial fluid), or can be contacted with ionic solutions to initiate assembly.
To increase the bio-availability of minerals, in a first stage of treatment, a microorganism extract is mixed with mineral(s). In a second, the mixture is concentrated. In a third stage, the concentrated product is spray-dried. The microorganism extract is from a yeast, particularly originating from a strain of Saccharomyces Cerevisiae or Saccharomyces Boulardii. The extract is in hydrated form, is a powder, microgranules, lyophiles, or it is spray dried. The mineral includes Ca, K, Mg or trace elements. It is mono-, tri- or hexavalent, containing e.g. Fe, Zn, Mn, Cr, Cu or Li. It is an inorganic salt which can be hydrolyzed, e.g. a chloride or sulfate. It is organic, a citrate, fumarate, gluconate or a lactate. Suitable salts corresponding with the foregoing are listed. Mixing is preferably at 20[deg]C-30[deg]C. Concentration is by evaporation under vacuum, or by membrane nanofiltration, reverse osmosis or constant volume diafiltration. The membrane filtration threshold is 100-300 Daltons, preferably 150-250 Daltons. During atomization the product is dried in contact with an airflow at preferably 170[deg]C-190[deg]C. An independent claim is included for the corresponding food product.
After obtaining baseline data and questionnaires, patients will receive usual care (for example physical therapy, oral pain medication or ointments), plus acupuncture 2X/week over 2 weeks, then once per week over 8 weeks (12 total treatments over 10 weeks), then no acupuncture between 10 weeks and 6 months. After treatment is completed, final measurement instruments are applied at 6 months. Questionnaires will be readministered at 2.5 and 6 months.
The number of participants in this group is 30. All participants were included in the rehabilitation program using only the Neurodevelopmental Therapy approach for 16 sessions (8 weeks x 2 days x 45 minutes).
Lesion mimic mutants (LMMs) refer to the spontaneous formation of disease-like spots on leaves without any obvious pathogen infection. The LMM genes can regulate plant immunity, thus promoting the defense of crops against pathogens. However, there is a lack of systematic understanding of the regulatory mechanism of LMMs in wheat. This study identified a wheat LMM TaCAT2, a homolog of the Arabidopsis CAT2. The prediction of the cis-regulatory element revealed that TaCAT2 was involved in the response of plants to various hormones and stresses. RT-qPCR analysis indicated that TaCAT2 was significantly up-regulated by NaCl, drought, and Fusarium graminearum infection. Fluorescence microscopy showed that the TaCAT2 was localized to the peroxisome. Overexpression of TaCAT2 enhanced plant resistance to Phytophthora infestation and F. graminearum by constitutionally activating SA and JA pathways. VIGS of TaCAT2 enhanced the sensitivity of wheat to F. graminearum. Further, TaCAT2 enhanced stress resistance by scavenging the excessive ROS and increasing the activities of antioxidative enzymes. This study lays the basis for the functional identification of TaCAT2 and its applicability in the disease resistance of wheat.
Patients receive cyclophosphamide intravenously IV on days -5 and -4, and fludarabine IV on days -5 to -2. Patients then receive autologous IL13(EQ)BBzeta/CD19t+ T cells intraventricularly over 5 minutes QW on day 0. Treatment with autologous IL13(EQ)BBzeta/CD19t+ T cells repeats every 7 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional cycles of IL13(EQ)BBzeta/CD19t+ T cells as long as they continue to meet eligibility criteria and have doses available for infusion.
INTRODUCTION: Sepsis-induced acute kidney injury (AKI) remains a major challenge in intensive care, contributing significantly to morbidity and mortality. Tibolone, known for its neuroprotective and hormonal properties, has not been explored for its potential in AKI management. This study investigates the protective effects of Tibolone and its underlying mechanisms involving Sirtuin-1 (SIRT1) and Yes-Associated Protein (YAP) in a rat sepsis model.
MATERIALS AND METHODS: Thirty-six female Wistar albino rats underwent cecal ligation and puncture (CLP) to induce sepsis. They were randomly assigned to control, CLP+Saline, and CLP+Tibolone groups. Tibolone was administered intraperitoneally. Biomarkers, including Sirtuin (SIRT1), Yes-associated protein (YAP), Tumor necrosis factor (TNF-α), High mobility group box 1 (HMGB1), malondialdehyde (MDA), creatinine, and urea, were assessed. Histopathological examination evaluated renal damage.
RESULTS: Tibolone administration significantly reduced plasma TNF-α, HMGB1, MDA, creatinine, and urea levels compared to the CLP+Saline group. Moreover, Tibolone elevated SIRT1 and YAP levels in kidney tissues. Histopathological examination demonstrated a significant decrease in tubular epithelial necrosis, luminal debris, dilatation, hemorrhage, and interstitial inflammation in Tibolone-treated rats.
CONCLUSION: This study unveils the protective role of Tibolone against sepsis-induced AKI in rats. The improvements in inflammatory and oxidative biomarkers and histological evidence suggest Tibolone's potential as a therapeutic intervention in sepsis-associated kidney injury. The upregulation of SIRT1 and YAP indicates their involvement in Tibolone's renoprotective mechanisms. Further investigations are warranted to explore Tibolone's translational potential in human sepsis-induced AKI.
In arterial hypertension, the dysregulation of several metabolic pathways is closely associated with chronic immune imbalance and inflammation progression. With time, these disturbances lead to the development of progressive disease and end-organ involvement. However, the influence of cholecalciferol on metabolic pathways as a possible mechanism of its immunomodulatory activity in obesity-related hypertension is not known. In a phase 2, randomized, single-center, 24-week trial, we evaluated, as a secondary outcome, the serum metabolome of 36 age- and gender-matched adults with obesity-related hypertension and vitamin D deficiency, before and after supplementation with cholecalciferol therapy along with routine medication. The defined endpoint was the assessment of circulating metabolites using a nuclear magnetic resonance-based metabolomics approach. Univariate and multivariate analyses were used to evaluate the systemic metabolic alterations caused by cholecalciferol. In comparison with normotensive controls, hypertensive patients presented overall decreased expression of several amino acids (p < 0.05), including amino acids with ketogenic and glucogenic properties as well as aromatic amino acids. Following cholecalciferol supplementation, increases were observed in glutamine (p < 0.001) and histidine levels (p < 0.05), with several other amino acids remaining unaffected. Glucose (p < 0.05) and acetate (p < 0.05) decreased after 24 weeks in the group taking the supplement, and changes in the saturation of fatty acids (p < 0.05) were also observed, suggesting a role of liposoluble vitamin D in lipid metabolism. Long-term cholecalciferol supplementation in chronically obese and overweight hypertensives induced changes in the blood serum metabolome, which reflected systemic metabolism and may have fostered a new microenvironment for cell proliferation and biology. Of note, the increased availability of glutamine may be relevant for the proliferation of different T-cell subsets.
Human brains vary across people and over time; such variation is not yet understood in cellular terms. Here we describe a relationship between people's cortical neurons and cortical astrocytes. We used single-nucleus RNA sequencing to analyse the prefrontal cortex of 191 human donors aged 22-97 years, including healthy individuals and people with schizophrenia. Latent-factor analysis of these data revealed that, in people whose cortical neurons more strongly expressed genes encoding synaptic components, cortical astrocytes more strongly expressed distinct genes with synaptic functions and genes for synthesizing cholesterol, an astrocyte-supplied component of synaptic membranes. We call this relationship the synaptic neuron and astrocyte program (SNAP). In schizophrenia and ageing-two conditions that involve declines in cognitive flexibility and plasticity1,2-cells divested from SNAP: astrocytes, glutamatergic (excitatory) neurons and GABAergic (inhibitory) neurons all showed reduced SNAP expression to corresponding degrees. The distinct astrocytic and neuronal components of SNAP both involved genes in which genetic risk factors for schizophrenia were strongly concentrated. SNAP, which varies quantitatively even among healthy people of similar age, may underlie many aspects of normal human interindividual differences and may be an important point of convergence for multiple kinds of pathophysiology.
The present study is based on previous research pointing out that circulating miRNAs are abnormally expressed in several pathologies including endometriosis, and can be used as a handy diagnostic tool in the clinical setting. The investigators hypothesize that miRNAs are differentially expressed in adenomyosis as well and could serve as noninvasive biomarkers to diagnose the condition. To test this hypothesis, the investigators plan to conduct a pilot study on 50 patients (25 adenomyosis patients and 25 healthy subjects), in order to compare expression of different miRNAs between the groups and determine a suitable diagnostic panel. There is approximatively 25 women undergoing hysterectomy for adenomyosis over the course of a year at the CUSL. It is also a necessary population in order to obtain statistically analyzable datas. This panel may be tested in the future in a larger population for validation purposes.

Blood samples (10 ml) will be collected the day of the surgery by the anesthetist from female patients visiting the CUSL for the purpose of hysterectomy. Patients will be subdivided into two groups, namely the study group (n=25) including patients diagnosed with adenomyosis by MRI and/or ultrasonography prior surgery and the control group (n=25) consisting of patients with pathologies unrelated to the endometrium. After samples registration in CUSL biobank, they will be transferred to the research laboratory and serum will be collected immediately by centrifuging at 2500 rpm for 15 min at 4° C followed by storage at -80°C until further use. To isolate circulating miRNAs, a commercial kit (Qiagen miRNeasy serum/plasma kit) will be used and cDNA will be then synthesized using appropriate kit (Qiagen miScript II RT). Commercial miRNA arrays will be used to simultaneously quantify expression of around 1000 miRNAs and compare their expression profiles between adenomyosis patients and unaffected subjects. Individual RT-qPCR reactions will be then conducted to validate the results. Differentially expressed microRNAs in adenomyosis will be further analyzed to determine their target genes and subsequent affected biological functions, using appropriate databases (TargetScan and miRTarBase). This experimental approach will allow us to identify abnormally expressed miRNAs in adenomyosis compared to disease-free women. These can then be used as noninvasive biomarkers of the pathology and/or targeted for development of new therapeutic options.
The invention relates to a navel-dressing traditional Chinese medicine for treating the chronic diarrhea of an infant. The navel-dressing traditional Chinese medicine basically comprises the following raw materials: nutmeg, gorgon euryale seed and pomegranate peel. The navel-dressing traditional Chinese medicine for treating the chronic diarrhea of the infant basically comprises the following raw materials proportioned by weight: 1 to 3 parts of nutmeg, 1 to 3 parts of gorgon euryale seed, 0.5 to 1.5 parts of pomegranate peel, 1 to 3 parts of monkshood tuber and 1 to 3 parts of rhizoma zingiberis. The navel-dressing traditional Chinese medicine disclosed by the invention is simple in the use of the materials and is low in cost. The navel-dressing traditional Chinese medicine for treating the chronic diarrhea of the infant basically comprises the raw materials of the nutmeg, the gorgon euryale seed and the pomegranate peel, wherein the nutmeg for strengthening the spleen and relieving diarrhea with astringents and the gorgon euryale seed for strengthening the spleen and relieving diarrhea are used as a monarch medicine together, and the pomegranate peel for relieving diarrhea with astringents is used as a ministerial or conductant medicine. The curative effect is high, and the use is convenient and safe. The monkshood tuber and the rhizoma zingiberis are added on a basic formula for treating a person accompanied with fear to cold, cold limbs, cold pain in the abdomen and deficiency in spleen yang. By using the navel-dressing traditional Chinese medicine disclosed by the invention, the chronic diarrhea of the infant is treated by a navel-dressing treatment method, the dosage is little, and the action of acting is quick; and moreover, no toxic or side effect exists, and the effective rate in treatment is high.
The KD will follow general principles as we have described with the aim to achieve blood ketones \>0.5 mM, which will require most participants to consume \<50 g/day carbohydrate and \~1.5 g/kg reference weight protein. Fat will comprise the remaining calories with an emphasis on monounsaturated and saturated sources from whole foods.
What is presented is a computer-implemented method for behavioral prediction of mental health clients. A profile is created for each mental health client. The profile includes a framework for alerts to be generated. The framework comprises client specific deidentified data points, client specific weights assigned to each data point, and client specific triggering events based on each data point. Each mental health client is provided with a cell phone enabled with a GPS tracker and social media software applications. The created profile is associated with the cell phone and the social media software applications. The cell phone and the social media software applications are then monitored over time to identify data points and triggering events to generate a log of triggering events. The assigned weights are applied to each triggering event to determine whether or not an alert is generated. Historical patterns are analyzed to optimize the accuracy of future alerts.
Decorin, a small collagen-binding dermatan sulfate proteoglycan, is widely distributed as a component of extracellular matrices. Using a solid phase binding assay, the inventors demonstrated that decorin bound C1q at physiologic pH and ionic strength. The interaction did not require divalent cations and was time and temperature dependent reaching equilibrium in 4 hours at 37° C. Binding was specific and saturable with an apparent dissociation constant of 7.6×10 -9  M. Decorin was shown to bind pepsin-derived fragments containing the collagenous domain of C1q and collagenase-derived fragments containing the globular domain of C1q. Since these fragments share a short sequence of amino acids, this finding suggests that decorin binds to a region of C1q located near the junction of the two domains. Competition studies using purified preparations of the decorin core protein and the glycosaminoglycan chains showed that only the former inhibited binding of decorin to C1q indicating that the interaction is mediated by the decorin core protein. Decorin was shown to inhibit the hemolytic activity of purified C1 as well as C1 in normal human serum. Approximately 50% inhibition was observed at a decorin concentration of 2 μg/ml. Inhibition was not observed if C1 was bound to antigen-complexed antibody. Furthermore, neither the core protein, nor the glycosaminoglycan chain of decorin inhibited C1 indicating that the intact proteoglycan is necessary for functional activity. These studies therefore demonstrate the usefulness of decorin and related proteoglycans in suppression of complement activation of the immune system.